A comparison of the risk prediction models PERSARC and Sarculator in patients with localized soft tissue sarcoma of the extremities and trunk wall [0.03%]
PERSARC和Sarculator模型在四肢及躯干软组织肉瘤患者中风险预测的比较分析研究
M R Kobbeltvedt,I Lobmaier,M Spreafico et al.
M R Kobbeltvedt et al.
Background: Different risk classification criteria are used to select patients with localized soft tissue sarcoma of the extremities and trunk wall for neoadjuvant/adjuvant chemotherapy. The two most frequently used risk ...
Gene expression profiling in a retrospective real-world cohort of breast cancer brain metastases and paired primary tumors identifies biological changes with potential therapeutic implications [0.03%]
基于回顾性的真实世界乳腺癌脑转移队列的基因表达谱分析及与原发灶对比鉴定出可能具有潜在治疗意义的生物标志物变化规律
G Griguolo,M V Dieci,S Fineberg et al.
G Griguolo et al.
Background: Despite the clinical impact of breast cancer (BC) brain metastases (BMs), their biological complexity remains poorly understood. We evaluated the genomic profile of BCBMs and compared it with paired primary BC...
Efficacy of first-line treatments for advanced pulmonary sarcomatoid carcinomas: a real-world analysis [0.03%]
一线治疗方案对晚期肺肉瘤样癌疗效的现实世界研究分析
K Amrane,B Cabarrou,G Justeau et al.
K Amrane et al.
Background: Among the aggressive non-small-cell lung carcinoma subtypes, pulmonary sarcomatoid carcinoma (PSC) is a rare and poorly understood tumor. This study was undertaken to evaluate the efficacy [progression-free su...
CDX2 expression as a predictive and prognostic biomarker of 5-FU response in cancer of unknown primary [0.03%]
CDX2表达作为未知原发灶癌症对5-氟尿嘧啶反应的预测和预后生物标志物
H E Fuentes Bayne,R Suleiman,R A Eiring et al.
H E Fuentes Bayne et al.
Background: Cancer of unknown primary (CUP) remains a diagnostic and therapeutic challenge with limited treatment guidance. Caudal type homeobox 2 (CDX2), a transcription factor indicative of intestinal differentiation, m...
Durvalumab and tremelimumab plus local partial tumour ablation (radiofrequency ablation or stereotactic radiotherapy) in patients with unresectable liver metastases from metastatic colorectal cancer: results of the EORTC-1560-GITCG multicentre, single-arm phase II study (ILOC) [0.03%]
德瓦鲁单抗和曲美木单抗联合局部消融术(射频消融或立体定向放疗)治疗无法手术切除的转移性结直肠癌肝转移瘤患者的疗效:EORTC-1560-GITCG 单组 II 期临床试验(ILOC)结果
J Seligmann,T Koessler,M Mauer et al.
J Seligmann et al.
Background: Treatment strategies for metastatic colorectal cancer (mCRC) patients with unresectable liver metastases include systemic therapy and local ablative treatments (LATs). While immunotherapy outcomes in patients ...
Imaging of extranodal extension: why is it important in head and neck cancer? [0.03%]
咽旁间隙肿瘤外侵的影像评估及其临床意义
A D King,Y M Tsang,H S Leung et al.
A D King et al.
The assessment of extranodal extension by imaging (iENE) is important in the management of patients with metastatic nodes from head and neck cancer (HNC). Over many decades iENE has guided surgical and radiotherapy planning using both early...
Reply to letter comments on: Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, phase III umbrella trial (SAFIR-ABC10-Precision Medicine) [0.03%]
关于信件评论的回复:分子靶向维持治疗与标准护理在晚期胆道癌中的比较:一项国际、随机、对照、开放标签的Ⅲ期伞式试验(SAFIR-ABC10 精准医学)
D Malka,I Borbath,A Lopes et al.
D Malka et al.
A radiomics-based artificial intelligence model to assess the risk of relapse in localized colon cancer [0.03%]
基于影像组学的预测局部结肠癌复发风险的人工智能模型
C Prieto-de-la-Lastra,J A Carbonell-Asins,A Bueno et al.
C Prieto-de-la-Lastra et al.
Background: Accurately estimating relapse risk in localized colon cancer (LCC) remains a challenge, as clinicopathological staging often fails to differentiate patients with a higher likelihood of recurrence. There is a n...
Prognostic impact and clinical management of pT4N0 colon cancer: data from a large, multicenter, international, real-world dataset [0.03%]
pT4N0期结肠癌的预后影响及临床处理:来自大规模国际真实世界数据库的研究数据
V Daprà,A Gandini,F Schietroma et al.
V Daprà et al.
Background: T4 is one of the most important prognostic factors in localized colon cancer (CC), especially in stage II (pT4N0). However, the optimal adjuvant treatment in this subset of patients remains unclear. We present...
A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients [0.03%]
利妥昔木单抗暴露或复发多发性骨髓瘤患者的随机临床试验网络meta分析
E A Martino,G Caridà,D Lofaro et al.
E A Martino et al.
Background: The treatment landscape for relapsed/refractory multiple myeloma (RRMM) is rapidly evolving, particularly for patients exposed or refractory to lenalidomide. With the aim of evaluating the relative efficacy of...